Azitra, Inc. (AZTR)
Azitra, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Branford, CT, US. The stock last traded at $0.14, down 5.59% on the session, giving a market capitalisation of $1.5M. On trailing twelve-month figures it carries a trailing P/E of -0.05, a net margin of 0.0%. Its beta of -1.18 implies it has historically moved less than the broad market.
Azitra, Inc. is a pre-clinical biopharmaceutical company focused on developing precise treatments for various dermatological conditions. They innovate by utilizing engineered proteins and live biotherapeutic products to address skin diseases. The company's pipeline features several key therapeutic candidates: ATR-12: A genetically modified strain of S. epidermidis intended to treat Netherton syndrome, a specific skin disorder. ATR-04: Another modified S. epidermidis strain, designed to alleviate the papulopustular rash commonly experienced by cancer patients undergoing epidermal growth factor receptor inhibitor therapy. ATR-01: An engineered recombinant human filaggrin protein developed for the treatment of ichthyosis vulgaris, another dermatological ailment. Founded in 2014, Azitra, Inc. operates from its headquarters in Branford, Connecticut.
Azitra, Inc. is most often compared with the following Healthcare names: